Choose a language
In this CPhI Japan dedicated webinar, we will present how Stevanato Group solutions can support the biologic drug development.
Friday, November 20th – 2.15 to 2.45 pm (JST) / 6.15 - 6.30 am (CEST)
Kazunari Hattori - Regulatory affairs
By 2025 biologics are expected to be about 34% of the overall drug market versus about 23% registered in 2015: this progressive growth of biologics, including biosimilars, is driving the need for new container platforms.
This means that the primary packaging containers industry must support pharma companies with flexible solutions to cut TCO and to reduce the time-to-market starting from the early development stage.
Through Nexa® and Alba® glass containers devised for biologics and our ready to use platform, EZ-fill®, Stevanato Group can streamline the biologic drug development, improving operational efficiency, quality, safety, and time to market.
In this presentation, you will learn about our quality levels, the advantages of ready to use components, formats, and capabilities.